(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 14.39% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 37.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 21.94%.
Alpha Teknova's revenue in 2026 is $40,520,000.On average, 8 Wall Street analysts forecast TKNO's revenue for 2026 to be $2,359,143,232, with the lowest TKNO revenue forecast at $2,226,674,531, and the highest TKNO revenue forecast at $2,481,376,689. On average, 8 Wall Street analysts forecast TKNO's revenue for 2027 to be $2,669,630,146, with the lowest TKNO revenue forecast at $2,457,744,530, and the highest TKNO revenue forecast at $2,818,978,960.
In 2028, TKNO is forecast to generate $3,358,660,304 in revenue, with the lowest revenue forecast at $3,066,929,072 and the highest revenue forecast at $3,628,956,471.